Steven Patierno
Overview:
Patierno's current translational research interests are focused on the genomics molecular biology of cancer disparities, cancer biology, molecular pharmacology and targeted experimental therapeutics to control prostate, breast and lung tumor aggressiveness. He is an internationally recognized expert in cancer control, cancer causation and molecular carcinogenesis, which includes a broad spectrum of laboratory and population level research. Patierno is also actively engaged in cancer health disparities and healthcare delivery research focused on patient navigation, survivorship, community-based interventions, mHealth, implementation sciences, cancer care economics, and policy.
Positions:
Professor of Medicine
Medicine, Medical Oncology
School of Medicine
Professor of Pharmacology and Cancer Biology
Pharmacology & Cancer Biology
School of Medicine
Professor in Family Medicine and Community Health
Family Medicine and Community Health
School of Medicine
Core Faculty Member, Duke-Margolis Center for Health Policy
Duke - Margolis Center For Health Policy
Institutes and Provost's Academic Units
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Education:
B.S. 1981
University of Connecticut
Ph.D. 1985
University of Texas Medical School, Houston
Postdoctoral Training, Norris Comprehensive Cancer
University of Southern California
Grants:
3D Biology Signatures defined by Nanostring Max System
Administered By
Medicine, Medical Oncology
Awarded By
North Carolina Biotechnology Center
Role
Major User
Start Date
End Date
Identification of Genetic Determinates for Disparities in African American Patients with Non-Small Cell Lung Cancer
Administered By
Medicine, Medical Oncology
Awarded By
V Foundation for Cancer Research
Role
Significant Contributor
Start Date
End Date
Targeting RNA splicing in race-related aggressive and lethal prostate cancer
Administered By
Duke Cancer Institute
Awarded By
Prostate Cancer Foundation
Role
Principal Investigator
Start Date
End Date
PC150506: Small molecule targeting of RNA splice variants driving tumor aggressiveness
Administered By
Chemistry
Awarded By
United States Army Medical Research Acquisition Activity
Role
Collaborator
Start Date
End Date
2/2 NCCU-DUKE Cancer Disparities Translational Research Partnership
Administered By
Duke Cancer Institute
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date
Publications:
Abstract 750: Ancestry-related differentially spliced and expressed genes in prostate cancer
<jats:title>Abstract</jats:title>
<jats:p>Prostate cancer (PCa) affects disproportionally men from different population groups. The Surveillance, Epidemiology, and End Results Program’s (SEER’s) 2018 report reveals that PCa incidence and mortality rates are ~2 times higher among African American (AA) men in comparison with white men. In addition to differences in social, lifestyle and structural determinants of health, there is accumulating evidence for a biological contribution to racial disparity in PCa. To date, most work focused on understanding further the molecular mechanisms underlying racial disparity in PCa has analyzed differential aggregate gene expression and mutation among PCa from patients of different population groups. Our recently published work reported alternative RNA splicing (ARS) as a mechanism promoting tumor aggressiveness and drug resistance in PCa from AA patients. Here, we analyzed The Cancer Genome Atlas (TCGA) data using the Genomic Data Commons to analyze differential aggregate gene expression (2-fold mean change, p &lt; 0.001, Wilcoxon rank sum test) and TCGASpliceSeq to analyze ARS (20% median change, percent spliced in) between PCa from AA and white patients. From our analysis of the 307 PCa specimens from white patients and 49 PCa specimens from AA patients, we identified 71 differentially expressed genes (DEGs) and 73 differential RNA splicing events (DRSEs) between PCa from AA and white patients. 51 of the DEGs (~72%) exhibit increased expression levels in PCa from AA patients compared with white patients. Among the DRSEs, the majority involve exon skipping (35 events, ~48%). Notably, the genes that exhibit differential aggregate gene expression and the genes that undergo differential ARS do not overlap, indicating that ancestry-related differences in aggregate gene expression and ARS can be independent events. However, a significant number of the Gene Ontology terms corresponding to the genes exhibiting ancestry-related differential aggregate gene expression or differential ARS do overlap, indicating that, despite these two distinct mechanisms of regulation (transcription and RNA splicing), both differentially regulate common pathways in PCa between AA and white patients. In addition, we identified 10 trans-acting splicing factors (SFs), whose aggregate gene expression significantly differed between PCa from AA and white patients, suggesting a potential mechanistic relationship between these SFs and the identified DRSEs. These findings increase understanding of molecular mechanisms underlying racial disparity in PCa. Upon further study, such DEGs and DRSEs have the potential to be candidates for novel precision medicine interventions.</jats:p>
<jats:p>Citation Format: Muthana Al Abo, Daniel J. George, Jennifer A. Freedman, Steven R. Patierno. Ancestry-related differentially spliced and expressed genes in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 750.</jats:p>
Authors
MLA Citation
Abo, Muthana Al, et al. “Abstract 750: Ancestry-related differentially spliced and expressed genes in prostate cancer.” Cancer Research, vol. 79, no. 13_Supplement, American Association for Cancer Research (AACR), 2019, pp. 750–750. Crossref, doi:10.1158/1538-7445.am2019-750.
URI
https://scholars.duke.edu/individual/pub1417240
Source
crossref
Published In
Cancer Research
Volume
79
Published Date
Start Page
750
End Page
750
DOI
10.1158/1538-7445.am2019-750
Abstract PL02-02: Spliceomics: Alternative RNA splicing as a source of ancestry-related molecular targets in precision oncology and cancer disparities
Authors
MLA Citation
Patierno, Steven R. “Abstract PL02-02: Spliceomics: Alternative RNA splicing as a source of ancestry-related molecular targets in precision oncology and cancer disparities.” Experimental and Molecular Therapeutics, American Association for Cancer Research, 2019. Crossref, doi:10.1158/1538-7445.sabcs18-pl02-02.
URI
https://scholars.duke.edu/individual/pub1417391
Source
crossref
Published In
Experimental and Molecular Therapeutics
Published Date
DOI
10.1158/1538-7445.sabcs18-pl02-02
Modifiable patient-reported factors associated with cancer-screening knowledge and participation in a community-based health assessment.
BACKGROUND: We sought to identify modifiable factors associated with cancer screening in a community-based health assessment. METHODS: 24 organizations at 47 community events in central North Carolina distributed a 91-item survey from April-December 2017. Responses about (1) interest in disease prevention, (2) lifestyle choices (e.g., diet, tobacco), and (3) perceptions of primary care access/quality were abstracted to examine their association with self-reported screening participation and knowledge about breast, prostate, and colorectal cancer. RESULTS: 2135/2315 participants (92%; 38.5% White, 38% Black, 9.9% Asian) completed screening questions. >70% of screen-eligible respondents reported guideline-concordant screening. Healthy dietary habits were associated with greater knowledge about breast and colorectal cancer screening; reporting negative attitudes about and barriers to healthcare were associated with less breast, prostate, and colorectal cancer screening. Having a place to seek medical care (a proxy for primary care access) was independently associated with being ∼5 times as likely to undergo colorectal screening (OR 4.66, 95% CI 1.58-13.79, all p < 0.05). CONCLUSIONS: In this diverse, community-based sample, modifiable factors were associated with screening engagement, highlighting opportunities for behavioral intervention.
Authors
Fayanju, OM; Oyekunle, T; Thomas, SM; Ingraham, KL; Fish, LJ; Greenup, RA; Oeffinger, KC; Zafar, SY; Hyslop, T; Hwang, ES; Patierno, SR; Barrett, NJ
MLA Citation
Fayanju, Oluwadamilola M., et al. “Modifiable patient-reported factors associated with cancer-screening knowledge and participation in a community-based health assessment.” Am J Surg, vol. 225, no. 4, Apr. 2023, pp. 617–29. Pubmed, doi:10.1016/j.amjsurg.2022.10.059.
URI
https://scholars.duke.edu/individual/pub1555407
PMID
36411107
Source
pubmed
Published In
Am J Surg
Volume
225
Published Date
Start Page
617
End Page
629
DOI
10.1016/j.amjsurg.2022.10.059
Changing the landscape of non-small cell lung cancer disparities.
In the United States, lung and bronchus cancers are the second most common types of cancer and are responsible for the largest number of deaths from cancer, with African Americans suffering disproportionately from lung and bronchus cancers. This disparity likely results from a complex interplay among social, psycho-social, lifestyle, environmental, health system, and biological determinants of health. Toward improving outcomes for lung cancer patients of all races and ethnicities and mitigating lung cancer disparities, in this commentary, we bring forward biological factors that contribute to lung cancer disparities, efforts to identify, functionally characterize, and modulate novel ancestry-related RNA splicing-related targets in lung cancer for precision intervention, and translational and clinical research needs to improve outcomes for lung cancer patients of all races and ethnicities and mitigate lung cancer disparities.
Authors
MLA Citation
Odera, Joab O., et al. “Changing the landscape of non-small cell lung cancer disparities.” J Cancer Biol, vol. 2, no. 2, 2021, pp. 33–38. Pubmed, doi:10.46439/cancerbiology.2.020.
URI
https://scholars.duke.edu/individual/pub1532536
PMID
35929605
Source
pubmed
Published In
J Cancer Biol
Volume
2
Published Date
Start Page
33
End Page
38
DOI
10.46439/cancerbiology.2.020
Assessing the relationship between self-efficacy and socioeconomic status using the communication and attitudinal self-efficacy general scale
Authors
Rodday, AM; Parsons, SK; Calhoun, E; Dudley, D; Patierno, SR; Post, DM; Simon, MA; Warren-Mears, V; Freund, K
MLA Citation
Rodday, Angie Mae, et al. “Assessing the relationship between self-efficacy and socioeconomic status using the communication and attitudinal self-efficacy general scale.” Quality of Life Research, vol. 25, SPRINGER, 2016, pp. 156–57.
URI
https://scholars.duke.edu/individual/pub1250671
Source
wos
Published In
Quality of Life Research
Volume
25
Published Date
Start Page
156
End Page
157

Professor of Medicine
Contact:
10 Bryan Searle Drive, Seeley Mudd Building, Suite 413, Durham, NC 27710
Dumc-3917, Durham, NC 27710